Seres Therapeutics, Inc. Net Income Loss

• Seres Therapeutics, Inc. showed an increase of +4,088.2% in Net Income Loss from 2024 to 2025.
• This data is from Seres Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
• XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 13 years of available data (2013 to 2025), Seres Therapeutics, Inc.'s Net Income Loss has grown by 193.3%.
• Historical annual values: Fiscal year 2025: $5.70 million | Fiscal year 2024: $136.0 thousand | Fiscal year 2023: -$113.72 million | Fiscal year 2022: -$250.16 million | Fiscal year 2021: -$65.58 million | Fiscal year 2020: -$89.13 million | Fiscal year 2019: -$70.28 million | Fiscal year 2018: -$98.94 million | Fiscal year 2017: -$89.38 million | Fiscal year 2016: -$91.58 million | Fiscal year 2015: -$54.78 million | Fiscal year 2014: -$16.71 million | Fiscal year 2013: -$6.10 million.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026